WuXi AppTec

WuXi AppTec

Type	Private
Industry	Contract Research Organizations Pharmaceutical Biopharmaceutical Medical Devices
Founded	2000
Headquarters	Shanghai, China
Number of locations	18 including China (Shanghai, Suzhou, Wuxi, Wuhan, Tianjin, Jinshan, Changzhou, Nanjing); US (St. Paul, MN, San Diego, CA, Philadelphia, PA, Atlanta, GA, Plainsboro, NJ, Cambridge, MA); Iceland (Reykjavik); Israel (Tel Aviv); South Korea (Seongnam); Germany (Munich)
Key people	Ge Li (CEO)
Products	Discovery Services Lab Testing Division (LTD) API Development and Manufacturing (STA) Development Services WuXi Biologics Cell & Gene Therapy Services U.S. Medical Device Services Chemistry Services Toxicology Services Bioanalytical Services Clinical and Regulatory Services Genomics and molecular diagnostics Biological Reagents
Number of employees	>14,000 (2017) [1]
Website	Official website

WuXi AppTec Group (pronounced WOO-shee) is a global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company that is pioneering a new model of open-access research for companies ranging from big pharma right through to a single researcher. The WuXi Group offers an integrated portfolio of services to help worldwide customers and partners shorten discovery and development and lower the overall cost of drug and medical device R&D. The company covers the entire development cycle through five core operations, including its capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics. The WuXi platform is currently being used by over 3,000 innovative collaborators from more than 30 countries.^[2]

History

WuXi's founder, Dr Ge Li earned his doctorate in organic chemistry from Columbia University, and was a founding scientist at Pharmacopeia, Inc. of Princeton, New Jersey, then returned to China to found WuXi PharmaTech in Shanghai in December 2000.

WuXi Group established services in synthetic chemistry in 2001, manufacturing process development in 2003, research manufacturing in 2004, bioanalytical services in 2005, service biology in 2006, and toxicology and formulation in 2007. On December 14, 2006, WuXi PharmaTech, announced that it was named 173rd on the Deloitte Technology Fast 500 Asia Pacific 2006 ranking^[3] The company opened chemistry facilities in Tianjin in 2007. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. WuXi opened a toxicology facility in Suzhou in 2009.^[4]

WuXi opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in Shanghai and Wuxi city in 2011. At the same year, WuXi acquired MedKey, a China-based clinical research company, and Abgent, a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery. In 2012, WuXi opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi city. That year WuXi also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 antibody for rheumatoid arthritis for the Chinese market. In 2013, WuXi formed a joint venture with the global clinical contract research organization PRA International (now called PRA Health Sciences) to build a clinical research business in China.

In 2014, WuXi opened a new biologics biosafety testing facility in Suzhou. In the same year, WuXi acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. WuXi acquired NextCODE Health, a genomic analysis and bioinformatics company with operations in the United States and Iceland in 2015. That year, WuXi completed its merger (the "Merger") with WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of New WuXi Life Science Limited ("Parent"). As a result of the Merger, Parent acquired the Company in a cash transaction valued at approximately US$3.3 billion. In 2016, WuXi’s STA subsidiary opened new campus in Changzhou and operations in San Diego. In the same year, WuXi acquired Crelux GmbH, a structure-based drug discovery provider based in Munich, Germany. In 2017, WuXi acquired HD Biosciences (HDB), a biology focused preclinical drug discovery contract research organization (CRO).

Company segments

WuXi AppTec Group provides services to its customers primarily in the pharmaceutical, biotech, and other life science industries as well as research institutes, disease-focused and non-profit foundations. There are 5 areas of focus for services: (1) Small Molecule Therapeutics R&D, Manufacturing and Testing (2) Biologicals Therapeutics R&D and Manufacturing, (3) Gene- and Cell-base Therapies Manufacturing, (4) Medical Device Testing, and (5) Genomics and Molecular Diagnostics.

References

External links

• Official website